Search over 3,000 reports

    Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017

    Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 149
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0002

    DelveInsight's, "Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Immune Checkpoints Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
    Scope
    - The report provides competitive pipeline landscape of Immune Checkpoints Activators
    - The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    - The report provides the insight of current and future market for Immune Checkpoints Activators
    - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    - Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    - The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
    - The report also gives the information of dormant pipeline projects
    - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
    '
    Reasons to Buy
    - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    - Complete MOA intelligence and complete understanding over therapeutics development for Immune Checkpoints Activators
    - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    - Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
    - Developing strategic initiatives to support your drug development activities.
    - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Executive Summary
    Executive Summary Snapshot
    Immune checkpoints Activator Overview
    Rationale for targeting Immune checkpoint Agonist in oncology
    Stimulatory checkpoint molecules
    Advantages of Immune checkpoint Activators
    Constraints of Immune Checkpoint Activators
    Future of Immune Checkpoint Activators in Cancer Therapy
    ImmuneCheck Activators Analysis
    ImmuneCheck Activators- Market Analysis
    Companies received Grants for Immune checkpoints Activator
    Companies Investment Details for Future Development
    Licensing Opportunities
    Market Drivers
    Market Barriers
    ImmuneCheck Activators - Pipeline Analysis
    Number of Products
    Therapeutic Areas Targeted
    Stages of Development
    Companies Involved
    Technological Platform Utilized
    Clinical Trials Analysis
    Clinical Products and Study Completion Year
    Studies Analysisfor the Key Targets Antigens
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I)
    Comparative Analysis
    Pre-Clinical and Discovery Products
    Comparative Analysis
    Therapeutic Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Route of Administration
    Assessment by Stage and Route Of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Discontinued Products
    Comparative Analysis
    Appendix
    DelveInsight Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer

    Table 1: B7 & CD28 Family Members
    Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
    Table 3: Companies of Immune checkpoints Activators received grants, 2017
    Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
    Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
    Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
    Table 7: ImmuneCheck Activators Targets Antigens and Companies
    Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
    Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
    Table 10: Number of Products under Development by Companies, 2017
    Table 11: Mid Stage Products (Phase II), 2017
    Table 12: Early Stage Products (Phase I ), 2017
    Table 13:Pre-Clinical and Discovery Products, 2017
    Table 14: Assessment by Monotherapy Products, 2017
    Table 15: Assessment by Combination Products, 2017
    Table 16: Assessment by Route Of Administration, 2017
    Table 17: Assessment by Stage and Route Of Administration, 2017
    Table 18: Assessment by Molecule Type, 2017
    Table 19:Assessment by Stage and Molecule Type, 2017
    Table 20: Discontinued Products, 2017
     

    Figure 1: Types of Immune Checkpoint receptors
    Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
    Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
    Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
    Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
    Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
    Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
    Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
    Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
    Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
    Figure 11: Mid Stage Products (Phase II), 2017
    Figure 12:Early Stage Products (Phase I and IND), 2017
    Figure 13:Pre-Clinical and Discovery Products, 2017
    Figure 14: Assessment by Monotherapy Products, 2017
    Figure 15: Assessment by Combination Products, 2017
    Figure 16: Assessment by Route of Administration, 2017
    Figure 17: Assessment by Stage and Route of Administration, 2017
    Figure 18: Assessment by Molecule Type, 2017
    Figure 19: Assessment by Stage and Molecule Type, 2017
    Figure 20:Discontinued Products, 2017

    TNFR/TNF
    Urelumab
    MEDI1873
    TRX518
    Solid Tumour
    Colorectal Cancer
    Non Small Cell Lung Cancer
    B- cell malignancies
    Ovarian Cancer
    Varilumab
    CD137
    Five Prime Therapeutics
    Inhibrx
    Agenus
    Incyte Corporation
    Leap Therapeutics
    Agenus
    Apexigen
    Kymab
    Pfizer
    Genentech
    Five Prime Therapeutics
    Inhibrx
    Agenus
    Incyte Corporation
    Leap Therapeutics
    Agenus
    Apexigen
    Kymab
    Pfizer
    Genentech
    MedImmune LLC
    • Single User License
      $2,950.00
    • Site License
      $5,900.00
    • Global License
      $8,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap